Oculis Holding (OCS) said Thursday that it has completed enrollment in two late-stage trials of OCS-01 eye drops in diabetic macular edema.
The trials, which enrolled more than 800 patients from the US and other countries, will assess the eye drops' efficacy and safety after 52 weeks of treatment, the company said.
The company said topline data from both trials is expected in Q2 of next year, followed by the submission of a new drug application.
Oculis shares were up 5.7% in recent premarket activity Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.